Deutsche Securities Japan Pharmaceutical Conference 2007



Hideaki Matsui Executive Vice President (Representative Executive Officer) Management Affairs, Human Resources Eisai Co., Ltd.





Safe Harbor Statement

- Materials and information provided during this presentation may contain socalled "forward-looking statements." These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements.
- Risks and uncertainties include general industry and market conditions, and general domestic and international economic conditions such as interest rate and currency exchange fluctuations. Risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, technological advances and patents attained by competitors; challenges inherent in new product development, including completion of clinical trials; claims and concerns about product safety and efficacy; obtaining regulatory approvals; domestic and foreign healthcare reforms; trends toward managed care and healthcare cost containment; and governmental laws and regulations affecting domestic and foreign operations.
- Also, for products that are approved, there are manufacturing and marketing risks and uncertainties, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials, and failure to gain market acceptance.
- The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.



- Lack of materials for pharmaceuticals
- Increasing difficulty in conducting clinical trials
- Medical contribution through new technology and provision of pharmaceuticals at low price
- Requirement of continuous investment in future growth while increasing P/L cost burden in near term
- Shift from P/L Management to Value Creation Management
- Requirement for continuous governance revolution prior to external environmental changes



System for Achieving Increased Corporate Value





System for Achieving Shareholder Value (1)

Committee Members


Nov 1999	Established Compliance Committee		Committee	Director	Outside Director	Chair
June 2000	Introduced Executive Officer System and selected outside directors					
		Nominating				Outside
	Established Corporate Governance Committee	Committee	3	-	3	Outside Director
Mar 2001	Established Corporate Governance Guideline					
	(Revised as needed afterwards)	Audit Committee	5	2	3	Outside Director
Jun 2003	eparated the roles of Chair of the Board and					
	President and CEO					
	Added Corporate Concept in the articles of	Compensation Committee	3	-	3	Outside Director
	incorporation					
Jun 2004	Adopted a "Company with Committees System"					
Jun 2005	Appointed an outside director to the post of	Independent Committee of Outside Directors	7	-	7	Outside Director
	Chair of the Board					
Sept 2005	Established Special Committee					
·						
Feb 2006	Established Independent Committee of Outside Directors					

September 28, 2007





System for Achieving Shareholder Value (2)



September 28, 2007





January, 1994 Issue of "Pharmacia"

Dreamer in a pharmaceutical company in the 21st century - Haruo Naito

Q: What does Eisai want to achieve? What does Eisai do?

A: Eisai wants to create a dream and give hope to patients

Added Corporate Concept to Article 2 of Incorporation





8





Governance Accounting FY2006



Balance Sheet

Total Sales: 674.1 Billion Yen





September 28, 2007

